Interline Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 39

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $50M

  • Investors
  • 3

Interline Therapeutics General Information

Description

Operator of a drug discovery firm intended to focus on systematically elucidating protein communities to define molecular mechanisms of disease. The company's firm leverages recent advancements in genomics, proteomics, structural biology, and computational chemistry to develop a precision medicine platform, enabling clients to identify new medicines targeting genetically validated signaling pathways and ensure that drug candidates comprehensively correct dysfunctional disease networks.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1400 Sierra Point Parkway
  • Suite 300
  • Brisbane, CA 94005
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1400 Sierra Point Parkway
  • Suite 300
  • Brisbane, CA 94005
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Interline Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC 16-Nov-2021 $50M Completed Generating Revenue
2. Early Stage VC (Series A) 04-Mar-2021 Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Interline Therapeutics’s complete valuation and funding history, request access »

Interline Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-2
Series A-1
Seed 10,100,000 $0.000100 $1 $1 1x $1 18.45%
To view Interline Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Interline Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a drug discovery firm intended to focus on systematically elucidating protein communities to define molecula
Drug Discovery
Brisbane, CA
39 As of 2024

Schlieren, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Interline Therapeutics Competitors (1)

One of Interline Therapeutics’s competitors is Dualsystems Biotech, a Formerly VC-backed company based in Schlieren, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dualsystems Biotech Formerly VC-backed Schlieren, Switzerland
You’re viewing 1 of 1 competitors. Get the full list »

Interline Therapeutics Patents

Interline Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025212514-A2 Methods of treating inflammatory diseases Pending 02-Apr-2024
WO-2025212514-A3 Methods of treating inflammatory diseases Pending 02-Apr-2024
AU-2024284173-A1 Methods of treating inflammatory diseases Pending 09-Jun-2023
AU-2024286701-A1 Methods of treating inflammatory diseases Pending 09-Jun-2023
EP-4724437-A1 Methods of treating inflammatory diseases Pending 09-Jun-2023 A61K31/437
To view Interline Therapeutics’s complete patent history, request access »

Interline Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Interline Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Resolved Ventures Venture Capital Minority
ARCH Venture Partners Venture Capital Minority
Foresite Capital Growth/Expansion Minority
To view Interline Therapeutics’s complete investors history, request access »

Interline Therapeutics FAQs

  • When was Interline Therapeutics founded?

    Interline Therapeutics was founded in 2020.

  • Where is Interline Therapeutics headquartered?

    Interline Therapeutics is headquartered in Brisbane, CA.

  • What is the size of Interline Therapeutics?

    Interline Therapeutics has 39 total employees.

  • What industry is Interline Therapeutics in?

    Interline Therapeutics’s primary industry is Drug Discovery.

  • Is Interline Therapeutics a private or public company?

    Interline Therapeutics is a Private company.

  • What is Interline Therapeutics’s current revenue?

    The current revenue for Interline Therapeutics is .

  • How much funding has Interline Therapeutics raised over time?

    Interline Therapeutics has raised $142M.

  • Who are Interline Therapeutics’s investors?

    Resolved Ventures, ARCH Venture Partners, and Foresite Capital have invested in Interline Therapeutics.

  • Who are Interline Therapeutics’s competitors?

    Dualsystems Biotech is a competitor of Interline Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process